GIC
ALNY icon

Generali Investments CEE’s Alnylam Pharmaceuticals ALNY Stock Holding History

Generali Investments CEE’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
3,850
+950
+33% +$287K 0.06% 270
2026
Q1 		$960K Hold
2,900
– – 0.05% 287
2025
Q4 		$1.15M Hold
2,900
– – 0.08% 234
2025
Q3 		$1.32M Hold
2,900
– – 0.1% 211
2025
Q2 		$946K Hold
2,900
– – 0.08% 239
2025
Q1 		$783K Hold
2,900
– – 0.07% 247
2024
Q4 		$682K Buy
+2,900
New +$763K 0.07% 235

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Generali Investments CEE's ALNY Position: Q2 2026 in Review

Generali Investments CEE increased its Alnylam Pharmaceuticals (ALNY) stake by 33% in Q2 2026, buying an estimated $287K and bringing the position to 3,850 shares worth $1.16M. The position accounts for 0.06% of the portfolio, ranked #270.

Generali Investments CEE first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.32M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Generali Investments CEE held 3,850 shares of Alnylam Pharmaceuticals worth $1.16M as of Q2 2026.
  • Generali Investments CEE bought 950 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $287K.
  • Alnylam Pharmaceuticals made up 0.06% of Generali Investments CEE's portfolio in Q2 2026, its #270 holding.
  • Generali Investments CEE first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Generali Investments CEE's Alnylam Pharmaceuticals position peaked at $1.32M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Generali Investments CEE's 13F filing for Q2 2026, filed 13 Jul 2026.